As Builders Firstsource (BLDR) Valuation Declined, Stadium Capital Management Lifted Stake; Alps Advisors Lifted Its Chemocentryx (CCXI) Position by $905,320

ChemoCentryx, Inc. (NASDAQ:CCXI) Logo

Alps Advisors Inc increased its stake in Chemocentryx Inc (CCXI) by 185.26% based on its latest 2018Q2 regulatory filing with the SEC. Alps Advisors Inc bought 69,640 shares as the company’s stock declined 9.17% while stock markets rallied. The institutional investor held 107,231 shares of the health care company at the end of 2018Q2, valued at $1.41M, up from 37,591 at the end of the previous reported quarter. Alps Advisors Inc who had been investing in Chemocentryx Inc for a number of months, seems to be bullish on the $490.10M market cap company. The stock increased 1.78% or $0.17 during the last trading session, reaching $9.7. About 128,998 shares traded. ChemoCentryx, Inc. (NASDAQ:CCXI) has risen 51.30% since November 23, 2017 and is uptrending. It has outperformed by 35.68% the S&P500. Some Historical CCXI News: 09/03/2018 – ChemoCentryx Expects to Utilize Between $65M-$75M Cash and Investments in FY18; 09/05/2018 – CHEMOCENTRYX INC – EXPECTS TO UTILIZE CASH AND INVESTMENTS BETWEEN $65 MLN AND $75 MLN FOR TWELVE MONTHS ENDING DECEMBER 31, 2018; 03/04/2018 – ChemoCentryx Presenting at Conference Apr 9; 09/03/2018 – CHEMOCENTRYX SEES 2018 CASH & INVESTMENTS USE $65M-$75M; 31/03/2018 – ChemoCentryx Conference Set By H.C. Wainwright for Apr. 8-10; 09/03/2018 – CCXI TO BEGIN AVACOPAN CLINICAL STUDIES IN HS BY ’18 END; 09/03/2018 – CHEMOCENTRYX INC QUARTERLY SHR $0.80; 09/03/2018 – ChemoCentryx Intends to Initiate Clinical Development of Avacopan in Hidradenitis Suppurativa by Yr-En; 09/03/2018 – CCXI PLANS TO START DEVT AVACOPAN IN HIDRADENITIS SUPPURATIVA; 22/03/2018 – ChemoCentryx Publishes Novel Findings of Role of CCR2 in Kidney Glomerulus, Supporting Advancement of CCR2 Inhibitor CCX140 in the Treatment of Focal Segmental Glomerulosclerosis (FSGS)

Stadium Capital Management Llc increased its stake in Builders Firstsource Inc (BLDR) by 9.71% based on its latest 2018Q2 regulatory filing with the SEC. Stadium Capital Management Llc bought 298,924 shares as the company’s stock declined 12.66% while stock markets rallied. The hedge fund held 3.38M shares of the consumer services company at the end of 2018Q2, valued at $61.76M, up from 3.08 million at the end of the previous reported quarter. Stadium Capital Management Llc who had been investing in Builders Firstsource Inc for a number of months, seems to be bullish on the $1.48 billion market cap company. The stock increased 2.96% or $0.37 during the last trading session, reaching $12.88. About 1.08 million shares traded. Builders FirstSource, Inc. (NASDAQ:BLDR) has risen 0.71% since November 23, 2017 and is uptrending. It has underperformed by 14.91% the S&P500. Some Historical BLDR News: 09/05/2018 – BUILDERS FIRSTSOURCE INC – EXPECT TO GENERATE $170-190 MLN IN CASH FROM OPERATIONS AND INVESTING IN 2018; 16/05/2018 – S&PGR Raises Builders FirstSource Rtgs To ‘BB-‘; Otlk Stable; 09/05/2018 – BUILDERS FIRSTSOURCE 1Q GROSS MARGIN +24.2%, EST. +24.2%; 21/04/2018 – DJ Builders FirstSource Inc, Inst Holders, 1Q 2018 (BLDR); 09/05/2018 – BUILDERS FIRSTSOURCE 1Q ADJ EPS 24C; 16/05/2018 – S&P REVISES BUILDERS FIRSTSOURCE INC. TO RATING ‘BB-‘ FROM ‘B+’; 07/03/2018 Norges Bank Buys New 1.3% Position in Builders First; 28/05/2018 – Builders FirstSource Access Event Set By Seaport for Jun. 4-5; 16/04/2018 – MUGATU: BLUE LINX? $BXCLE TIGRE?BUILDERS FIRST SOURCE? $BLDR THEY’RE THE SAME LOOK! DOESN’T ANYONE NOTICE THIS?I FEEL… h; 09/05/2018 – Builders FirstSource 1Q EPS 20c

Among 8 analysts covering ChemoCentryx (NASDAQ:CCXI), 4 have Buy rating, 1 Sell and 3 Hold. Therefore 50% are positive. ChemoCentryx had 12 analyst reports since September 3, 2015 according to SRatingsIntel. Zacks downgraded the shares of CCXI in report on Thursday, September 3 to “Sell” rating. The firm has “Buy” rating by JMP Securities given on Thursday, August 10. The company was maintained on Tuesday, August 8 by Cowen & Co. Canaccord Genuity maintained ChemoCentryx, Inc. (NASDAQ:CCXI) rating on Monday, November 12. Canaccord Genuity has “Buy” rating and $20 target. The stock has “Neutral” rating by JP Morgan on Tuesday, August 14. JP Morgan maintained the shares of CCXI in report on Tuesday, March 13 with “Overweight” rating. On Tuesday, February 21 the stock rating was initiated by JMP Securities with “Mkt Outperform”. The rating was downgraded by Zacks to “Sell” on Monday, September 21.

More recent ChemoCentryx, Inc. (NASDAQ:CCXI) news were published by: which released: “ChemoCentryx 2018 Q3 – Results – Earnings Call Slides” on November 08, 2018. Also published the news titled: “ChemoCentryx (CCXI) CEO Thomas Schall on Q3 2018 Results – Earnings Call Transcript” on November 09, 2018.‘s news article titled: “ChemoCentryx Reports Third Quarter 2018 Financial Results and Recent Highlights” with publication date: November 08, 2018 was also an interesting one.

Since June 26, 2018, it had 0 insider purchases, and 7 sales for $88.11 million activity. Cappel Markus J. had sold 25,179 shares worth $344,201. On Tuesday, October 16 the insider GLAXOSMITHKLINE PLC sold $85.85 million. Schall Thomas J. also sold $152,028 worth of ChemoCentryx, Inc. (NASDAQ:CCXI) shares.

Investors sentiment increased to 1.59 in Q2 2018. Its up 0.59, from 1 in 2018Q1. It increased, as 11 investors sold CCXI shares while 28 reduced holdings. 28 funds opened positions while 34 raised stakes. 26.37 million shares or 8.85% more from 24.22 million shares in 2018Q1 were reported. Northern Trust stated it has 0% in ChemoCentryx, Inc. (NASDAQ:CCXI). Bancorporation Of Ny Mellon Corp accumulated 118,778 shares or 0% of the stock. Susquehanna Intll Limited Liability Partnership reported 31,353 shares. Piermont Cap Mngmt owns 19,360 shares for 0.08% of their portfolio. 615,173 are owned by Nantahala Limited Company. Paw Cap holds 85,000 shares or 1.13% of its portfolio. Strs Ohio holds 0% or 60,200 shares. 197,230 were accumulated by Jpmorgan Chase & Co. Moreover, Jacobs Levy Equity Mngmt has 0.01% invested in ChemoCentryx, Inc. (NASDAQ:CCXI). Voya Investment Management Limited Liability Com has 10,588 shares. Her Majesty The Queen In Right Of The Province Of Alberta As Represented By Alberta Investment Corporation reported 44,500 shares. Federated Invsts Incorporated Pa holds 0% or 66,569 shares in its portfolio. Pnc Svcs Grp invested in 0% or 74 shares. Balyasny Asset Mngmt has 0% invested in ChemoCentryx, Inc. (NASDAQ:CCXI) for 11,125 shares. Fernwood Investment Management Limited Liability stated it has 0.07% in ChemoCentryx, Inc. (NASDAQ:CCXI).

Alps Advisors Inc, which manages about $13.32B and $15.33 billion US Long portfolio, decreased its stake in Health Care Select Sector Spdr (XLV) by 10,468 shares to 184,480 shares, valued at $15.40M in 2018Q2, according to the filing. It also reduced its holding in Industrial Select Sector Spdr (XLI) by 7,502 shares in the quarter, leaving it with 209,873 shares, and cut its stake in Huaneng Power International In (NYSE:HNP).

Among 14 analysts covering Builders Firstsource (NASDAQ:BLDR), 9 have Buy rating, 1 Sell and 4 Hold. Therefore 64% are positive. Builders Firstsource had 38 analyst reports since August 3, 2015 according to SRatingsIntel. The rating was maintained by FBR Capital with “Buy” on Thursday, March 1. The stock of Builders FirstSource, Inc. (NASDAQ:BLDR) has “Buy” rating given on Tuesday, January 16 by Stephens. FBR Capital maintained the stock with “Buy” rating in Thursday, June 7 report. FBR Capital maintained the shares of BLDR in report on Friday, November 10 with “Buy” rating. The rating was maintained by SunTrust with “Buy” on Friday, March 2. Stifel Nicolaus maintained Builders FirstSource, Inc. (NASDAQ:BLDR) on Sunday, January 21 with “Buy” rating. Seaport Global maintained it with “Buy” rating and $26.0 target in Tuesday, January 2 report. The firm has “Buy” rating given on Tuesday, September 8 by Deutsche Bank. The stock has “Buy” rating by B. Riley & Co on Friday, November 10. FBR Capital initiated it with “Outperform” rating and $16 target in Wednesday, June 1 report.

Another recent and important Builders FirstSource, Inc. (NASDAQ:BLDR) news was published by which published an article titled: “Builders FirstSource Reports Third Quarter 2018 Results” on November 01, 2018.

Investors sentiment decreased to 0.79 in 2018 Q2. Its down 0.24, from 1.03 in 2018Q1. It dropped, as 40 investors sold BLDR shares while 72 reduced holdings. 24 funds opened positions while 65 raised stakes. 89.53 million shares or 6.48% less from 95.73 million shares in 2018Q1 were reported. Eagle Asset Mngmt reported 0.42% in Builders FirstSource, Inc. (NASDAQ:BLDR). Patten Gru has invested 0% in Builders FirstSource, Inc. (NASDAQ:BLDR). Raymond James And Assoc accumulated 70,080 shares. Spitfire Cap Ltd stated it has 742,294 shares or 6.53% of all its holdings. Balyasny Asset Mngmt Ltd Liability accumulated 0.01% or 116,774 shares. Hennessy Advisors reported 1.76M shares stake. California Pub Employees Retirement accumulated 333,106 shares. Boston Ptnrs has 204,839 shares. Mckinley Capital Management Llc Delaware holds 4,466 shares. Perritt Capital Management Incorporated accumulated 32,600 shares or 0.17% of the stock. Goodhaven Capital Mngmt Ltd reported 170,900 shares. Swiss National Bank owns 196,300 shares or 0% of their US portfolio. Hbk LP reported 0.01% stake. Bowling Limited Liability invested in 97,230 shares or 0.25% of the stock. State Board Of Administration Of Florida Retirement reported 131,643 shares stake.

ChemoCentryx, Inc. (NASDAQ:CCXI) Institutional Positions Chart

Receive News & Ratings Via Email – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings with our FREE daily email newsletter.

Source link

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply

Your email address will not be published. Required fields are marked *